Using of inhaled antibiotics in the treatment of patients with community-acquired pneumonia

Antibiotics (AB) remain the main etiotropic drugs in the treatment of patients with community-acquired pneumonia (CAP). Long-term practice of antibiotic therapy has revealed not only the positive aspects of drugs of this group (reduction in mortality and the number of complications of CAP), but also disadvantages (development of resistance, side effects, including possible disorders of the cardiovascular system, etc.).It is especially important to avoid unwanted phenomena when using AB in people with such background pathological conditions as diabetes mellitus, severe systemic atherosclerosis, renal and hepatic damages. Therefore, recently the issue of inhalation administration of AB as an alternative to their systemic use has been very actively studied